Maraviroc, a CCR5 antagonist, prevents the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

被引：0
|
作者：
Perez-Martinez, L. [1 ]
Perez-Matute, P. [1 ]
Aguilera-Lizarraga, J. [1 ]
Rubio, S. [2 ]
Narro, J. [3 ]
Ochoa-Callejero, L. [3 ]
Oteo, J. A. [1 ]
Blanco, J. R. [1 ]
机构：
[1] Ctr Biomed Res La Rioja CIBIR, Infect Dis Area, Logrono, Spain
[2] Hosp San Pedro, Pathol Serv, Logrono, Spain
[3] Ctr Biomed Res Rioja La CIBIR, Oncol Area, Logrono, Spain
来源：
ANTIVIRAL THERAPY | 2013年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A69 / A69
页数：1
相关论文
共 50 条
  • [1] Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)
    Perez-Martinez, Laura
    Perez-Matute, Patricia
    Aguilera-Lizarraga, Javier
    Rubio-Mediavilla, Susana
    Narro, Judit
    Recio, Emma
    Ochoa-Callejero, Laura
    Oteo, Jose-Antonio
    Blanco, Jose-Ramon
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (07) : 1903 - 1910
  • [2] Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
    Ochoa-Callejero, Laura
    Perez-Martinez, Laura
    Rubio-Mediavilla, Susana
    Oteo, Jose A.
    Martinez, Alfredo
    Blanco, Jose R.
    [J]. PLOS ONE, 2013, 8 (01):
  • [3] MARAVIROC, A CCR5 ANTAGONIST, PREVENTS DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN A MOUSE MODEL
    Ochoa-Callejero, L.
    Perez, L.
    Rubio, S.
    Oteo, J. A.
    Martinez, A.
    Blanco, J. R.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S437 - S437
  • [4] Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model
    Ochoa-Callejero, Laura
    Perez-Martinez, Laura
    Rubio-Mediavilla, Susana
    Oteo, Jose A.
    Martinez, Alfredo
    Blanco, Jose R.
    [J]. CANCER RESEARCH, 2012, 72
  • [5] LPSF/GQ-02 Inhibits the Development of Hepatic Steatosis and Inflammation in a Mouse Model of Non-Alcoholic Fatty Liver Disease (NAFLD)
    Soares e Silva, Amanda Karolina
    Cipriano Torres, Dilenia de Oliveira
    dos Santos Gomes, Fabiana Oliveira
    Silva, Bruna dos Santos
    Ribeiro, Edlene Lima
    Oliveira, Amanda Costa
    Martins dos Santos, Laise Aline
    Alves de Lima, Maria do Carmo
    Pitta, Ivan da Rocha
    Peixoto, Christina Alves
    [J]. PLOS ONE, 2015, 10 (04):
  • [6] Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD)
    Nier, Anika
    Huber, Yvonne
    Labenz, Christian
    Michel, Maurice
    Bergheim, Ina
    Schattenberg, Joern M.
    [J]. NUTRIENTS, 2020, 12 (03)
  • [7] Sevelamer improves hepatic steatosis and modulates inflammation in a Western Diet mouse model of non-alcoholic fatty liver disease (NAFLD)
    McGettigan, Brett
    McMahan, Rachel
    Porsche, Cara
    Orlicky, David J.
    Wang, Xiaoxin
    Luo, Yuhuan
    Levi, Moshe
    Rosen, Hugo R.
    [J]. HEPATOLOGY, 2014, 60 : 746A - 747A
  • [8] Controlled Attenuation Parameter (CAP) for the detection of hepatic steatosis in alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD)
    Naveau, Sylvie
    Perlemuter, Gabriel
    Ziol, Marianne
    Carmona, Damien
    Trinchet, Jean Claude
    Prevot, Sophie
    Nohra, Pascal
    Nguefang-Njike, Micheline Nakseu
    Beaugrand, Michel
    [J]. HEPATOLOGY, 2012, 56 : 898A - 898A
  • [9] Ticagrelor, but not clopidogrel, attenuated hepatic steatosis in a model of non-alcoholic fatty liver disease
    Oh, Hyunwoo
    Lee, Hyo Young
    Park, Huiyul
    Jun, Dae Won
    Yoon, Eileen
    Ahn, Sang Bong
    Lee, Chul-min
    Kim, Mi Mi
    Kang, Bo-Kyeong
    Sohn, Joo Hyun
    [J]. JOURNAL OF HEPATOLOGY, 2022, 77 : S728 - S729
  • [10] Assessment of hepatic steatosis algorithms in non-alcoholic fatty liver disease
    Eremic-Kojic, N.
    Deric, M.
    Govorcin, M. L.
    Balac, D.
    Kresoja, M.
    Kojic-Damjanov, S.
    [J]. HIPPOKRATIA, 2018, 22 (01) : 10 - 16
12345